Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing
|
April 4, 2002
EULER-PCR: finishing experiments for repeat resolution
Zufar Mulyukov, Pavel A Pevzner
International Journal of Radiation Oncology, Biology, Physics
|
February 15, 2026
Estimation of maximum cumulative administered activity for radiopharmaceuticals in early clinical trials: assessing long-term toxicity risks of <sup>177</sup>Lu-DOTATATE
Zufar Mulyukov, Peter McCormack, Darlene Lu, et al.
Contemporary Clinical Trials
|
March 25, 2019
Dose-response analysis of ranibizumab as-needed regimens for visual improvement in patients with diabetic macular edema using a modelling approach
Yuan Xiong, Etienne Pigeolet, Zufar Mulyukov, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 26, 2018
Neovascular Age-Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect
Zufar Mulyukov, Sebastian Weber, Etienne Pigeolet, et al.
BMJ Open Ophthalmology
|
June 11, 2026
Alternative posology for brolucizumab: a 6-week loading regimen is as effective as a 4-week regimen for the treatment of nAMD
Zufar Mulyukov, Ufuk Olgac, Jeffrey D Kearns, et al.
BMC Bioinformatics
|
March 28, 2006
Automatic pathway building in biological association networks
Anton Yuryev, Zufar Mulyukov, Ekaterina Kotelnikova, et al.
Current Eye Research
|
February 18, 2020
Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data
Hansjürgen Agostini, Zufar Mulyukov, Miltiadis Tsilimbaris, et al.
Eye (London, England)
|
May 6, 2022
Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis
Ursula Schmidt-Erfurth, Zufar Mulyukov, Bianca S Gerendas, et al.
Retina (Philadelphia, Pa.)
|
December 19, 2021
EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and HARRIER Studies
Pravin U Dugel, Chirag D Jhaveri, Usha Chakravarthy, et al.
Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde
|
March 28, 2022
Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials
Michael Singer, Arshad M Khanani, Armin Wolf, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing
|
April 4, 2002
EULER-PCR: finishing experiments for repeat resolution
Zufar Mulyukov, Pavel A Pevzner
International Journal of Radiation Oncology, Biology, Physics
|
February 15, 2026
Estimation of maximum cumulative administered activity for radiopharmaceuticals in early clinical trials: assessing long-term toxicity risks of <sup>177</sup>Lu-DOTATATE
Zufar Mulyukov, Peter McCormack, Darlene Lu, et al.
Contemporary Clinical Trials
|
March 25, 2019
Dose-response analysis of ranibizumab as-needed regimens for visual improvement in patients with diabetic macular edema using a modelling approach
Yuan Xiong, Etienne Pigeolet, Zufar Mulyukov, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 26, 2018
Neovascular Age-Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect
Zufar Mulyukov, Sebastian Weber, Etienne Pigeolet, et al.
BMJ Open Ophthalmology
|
June 11, 2026
Alternative posology for brolucizumab: a 6-week loading regimen is as effective as a 4-week regimen for the treatment of nAMD
Zufar Mulyukov, Ufuk Olgac, Jeffrey D Kearns, et al.
BMC Bioinformatics
|
March 28, 2006
Automatic pathway building in biological association networks
Anton Yuryev, Zufar Mulyukov, Ekaterina Kotelnikova, et al.
Current Eye Research
|
February 18, 2020
Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data
Hansjürgen Agostini, Zufar Mulyukov, Miltiadis Tsilimbaris, et al.
Eye (London, England)
|
May 6, 2022
Therapeutic response in the HAWK and HARRIER trials using deep learning in retinal fluid volume and compartment analysis
Ursula Schmidt-Erfurth, Zufar Mulyukov, Bianca S Gerendas, et al.
Retina (Philadelphia, Pa.)
|
December 19, 2021
EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and HARRIER Studies
Pravin U Dugel, Chirag D Jhaveri, Usha Chakravarthy, et al.
Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde
|
March 28, 2022
Brolucizumab 12- and 16-Week Fixed Dosing Potential in Neovascular AMD: A post hoc Evaluation of Data from the HAWK and HARRIER Trials
Michael Singer, Arshad M Khanani, Armin Wolf, et al.
Page
of 2